Table 1 Changes from baseline in the Arg16Gly genotype at the end of 12 weeks of treatment with FSC
ADRB2 marker | Morning PEF (L/min) | FEV1(L) | Albuterol use (puffs/d) | Asthma symptom score |
|---|---|---|---|---|
Arg16Gly genotype | ||||
ArgArg(n = 21) | 114.4 ± 21.5 | 0.44 ± 0.09 | −3.81 ± 1.94 | −1.10 ± 0.78 |
ArgGly(n = 26) | 103.3 ± 23.7 | 0.43 ± 0.07 | −3.77 ± 1.95 | −0.96 ± 0.53 |
GlyGly(n = 15) | 100.3 ± 14.7 | 0.45 ± 0.11 | −3.80 ± 1.86 | −0.93 ± 0.59 |